Jack,
Since you've owned both, maybe you have a take on the issue that concerns me the most about this deal.
Management.
I have admired GLFD's science and financial savvy. But their ability to get profitable products to market worries me. I do not own GLFD but have followed it for years. It seems to me that GLFD had a leadership position in the neurotrophic therepeutic area that has now been frittered away. I do not understand their science deeply enough to know whether their drugs will take share from the ones that beat them to market.
I know next to nothing about GLIA, but I have seen some respected SI biotech posters dissing its management, too. I'm tempted to play the deal, anyhow, because I've been through enough of them now to know how stock prices generally react in the subsequent weeks. GLFD is likely close to a bottom, but if it doesn't join the rally soon, it could well join in on the next downturn.
Looks like we're going to get the summer rally out of the way by the middle of the month. Once the market falls back into a trading range, I'll be looking hard at buying GLFD.
Anyhow, curious about your take, and that of others, regarding the management of the new entity.
Cheers, Tuck |
